NCT03989609View on ClinicalTrials.gov

Dexmedetomidine in Modifying Immune Paralysis In Patient With Septic Shock

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

February 20, 2020

Study Completion Date

August 20, 2021

Conditions
Septic Shock
Interventions
DRUG

Dexmedetomidine Injection [Precedex]

Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,

DRUG

Midazolam

midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).

Trial Locations (1)

Unknown

Kasr Alainy Hospital , Faculty of Medicine, Cairo

All Listed Sponsors
lead

Kasr El Aini Hospital

OTHER

NCT03989609 - Dexmedetomidine in Modifying Immune Paralysis In Patient With Septic Shock | Biotech Hunter | Biotech Hunter